Litfulo?

Litfulo is a medication approved for treating severe alopecia areata in adults and adolescents 12 years and older [1]. It is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2 [2].

How does Litfulo work for alopecia areata?

Litfulo works by inhibiting Janus kinases (JAKs), which are involved in signaling pathways that contribute to inflammation [2]. In alopecia areata, these pathways are thought to play a role in the immune system attacking hair follicles [3]. By blocking JAK1 and JAK2, Litfulo helps to reduce this inflammation and promote hair regrowth [2].

What is the approval status of Litfulo?

Litfulo received FDA approval for severe alopecia areata in adults and adolescents aged 12 and older on June 26, 2023 [1].

What are the common side effects of Litfulo?

Common side effects reported with Litfulo include upper respiratory tract infections, headache, diarrhea, acne, and an increase in creatine kinase [2].

What serious risks are associated with JAK inhibitors like Litfulo?

As a JAK inhibitor, Litfulo carries potential serious risks that are also associated with other drugs in this class. These include serious infections, blood clots (e.g., deep vein thrombosis, pulmonary embolism), heart attack, stroke, cancer, and death [2]. Patients taking Litfulo are advised to monitor for signs of infection, blood clots, and other serious adverse events [2].

What is the mechanism of action for Litfulo?

Litfulo's mechanism of action involves the inhibition of Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. These enzymes are crucial in the signaling pathways of various cytokines and growth factors that mediate immune responses and hematopoiesis [2]. By blocking these pathways, Litfulo modulates the immune system's attack on hair follicles, which is implicated in alopecia areata [3].

Can children use Litfulo?

Litfulo is approved for use in adolescents aged 12 and older with severe alopecia areata [1].

How does Litfulo compare to other alopecia areata treatments?

Litfulo is one of several treatment options for severe alopecia areata. Other treatments may include topical or injectable corticosteroids, minoxidil, and other immunomodulatory therapies. Litfulo's approval as an oral JAK inhibitor offers a different approach to managing the condition [1, 3].

When might Litfulo patents expire?

Information on specific patent expiry dates for Litfulo would typically be available through specialized databases. DrugPatentWatch.com provides detailed patent information on numerous pharmaceuticals, which can be a resource for tracking patent exclusivity [4].

What are the clinical trial findings for Litfulo?

Clinical trials demonstrated that Litfulo led to significant hair regrowth in participants with severe alopecia areata. In one study, approximately 20% of patients achieved 80% or more scalp hair regrowth after 24 weeks of treatment [1].

What is the recommended dosage for Litfulo?

The recommended dosage for Litfulo in adults and adolescents 12 years and older with severe alopecia areata is 12 mg taken orally once daily [1].

Who manufactures Litfulo?

Pfizer Inc. manufactures Litfulo [1].

What are the contraindications for Litfulo?

Litfulo should not be used in patients with known hypersensitivity to litratinib or any of its excipients [2].

What monitoring is required for patients taking Litfulo?

Patients taking Litfulo require monitoring for signs and symptoms of serious infections, blood clots, and other adverse events. This may include regular laboratory tests and clinical assessments [2].

What is the typical duration of treatment with Litfulo?

The duration of treatment with Litfulo is typically determined by the patient's response and tolerance, and is managed under the supervision of a healthcare professional [1, 2].

Are there any known drug interactions with Litfulo?

Patients should inform their healthcare provider of all medications they are taking, as potential drug interactions with Litfulo may exist. This includes over-the-counter medications and herbal supplements [2].

What are the risks of developing cancer with JAK inhibitors?

There is an increased risk of developing certain cancers, including lymphoma and skin cancers, in patients taking JAK inhibitors. Patients should be monitored for any new skin lesions or other signs of malignancy [2].

What are the risks of cardiovascular events with Litfulo?

JAK inhibitors, including Litfulo, are associated with an increased risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death. Patients with risk factors for cardiovascular disease should be carefully evaluated [2].

What is the patient support program for Litfulo?

Information regarding patient support programs for Litfulo may be available through the manufacturer's website or patient assistance programs [1].

Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-litfulo-litratinib-treatment-severe-alopecia-areata
[2] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fda-approval-litfulo-litratinib-treatment-severe
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260706/
[4] https://drugpatentwatch.com/